Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nelipepimut-S

Known as: L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-, E75 Peptide, Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide 
A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract E75 (HER-2/neu-369–377), is an immunogenic peptide which is highly expressed in breast cancer patients. The purpose of… Expand
2017
2017
Early-phase clinical trials evaluating CD8+ T cell-eliciting, HER2-derived peptide vaccines administered to HER2+ breast cancer… Expand
2011
2011
The authors are conducting clinical trials of the HER‐2/neu E75‐peptide vaccine in clinically disease‐free breast cancer (BC… Expand
Highly Cited
2009
Highly Cited
2009
Purpose: HER2/neu, a source of immunogenic peptides, is expressed in >75% of breast cancer patients. We have conducted clinical… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2007
Highly Cited
2007
We used the Luminex assay to compare serum cytokine profiles of breast cancer patients (BCa) to healthy controls, node-positive… Expand
  • table I
  • figure 1
  • table II
  • figure 2
  • table III
Highly Cited
2006
Highly Cited
2006
E75 and GP2 are human leukocyte antigen (HLA)‐A2‐restricted immunogenic peptides derived from the HER2/neu protein. In a E75… Expand
2006
2006
Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2006
2006
We are conducting clinical trials of the E75 peptide as a vaccine in breast cancer (BrCa) patients. We assessed T cell… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2004
Highly Cited
2004
A pilot vaccine study was conducted to test the safety and immunological efficacy of four monthly immunizations of an MHC class I… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
2004
2004
HER2/neu is a proto-oncogene and a member of the epidermal growth factor receptor family of proteins that is overexpressed in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table I